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Abstract
Background: Ubiquitin ligases or E3 ligases are well programmed to regulate molecu-
lar interactions that operate at a post-translational level. Skp, Cullin, F-box containing
complex (or SCF complex) is a multidomain E3 ligase known to mediate the degrada-
tion of a wide range of proteins through the proteasomal pathway. The three-
dimensional domain architecture of SCF family proteins suggests that it operates
through a novel and adaptable “super-enzymatic” process that might respond to
targeted therapeutic modalities in cancer.
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Recent findings: Several F-box containing proteins have been characterized either as
tumor suppressors (FBXW8, FBXL3, FBXW8, FBXL3, FBXO1, FBXO4, and FBXO18)
or as oncogenes (FBXO5, FBXO9, and SKP2). Besides, F-box members like βTrcP1
and βTrcP2, the ones with context-dependent functionality, have also been studied
and reported. FBXW7 is a well-studied F-box protein and is a tumor suppressor.
FBXW7 regulates the activity of a range of substrates, such as c-Myc, cyclin E, mTOR,
c-Jun, NOTCH, myeloid cell leukemia sequence-1 (MCL1), AURKA, NOTCH through
the well-known ubiquitin-proteasome system (UPS)-mediated degradation pathway.
NOTCH signaling is a primitive pathway that plays a crucial role in maintaining normal
tissue homeostasis. FBXW7 regulates NOTCH protein activity by controlling its half-
life, thereby maintaining optimum protein levels in tissue. However, aberrations in
the FBXW7 or NOTCH expression levels can lead to poor prognosis and detrimental
outcomes in patients. Therefore, the FBXW7-NOTCH axis has been a subject of
intense study and research over the years, especially around the interactome's role in
driving cancer development and progression. Several studies have reported the effect
of FBXW7 and NOTCH mutations on normal tissue behavior. The current review
attempts to critically analyze these mutations prognostic value in a wide range of
tumors. Furthermore, the review summarizes the recent findings pertaining to the
FBXW7 and NOTCH interactome and its involvement in phosphorylation-related
events, cell cycle, proliferation, apoptosis, and metastasis.
Conclusion: The review concludes by positioning FBXW7 as an effective diagnostic
marker in tumors and by listing out recent advancements made in cancer therapeutics
in identifying protocols targeting the FBXW7-NOTCH aberrations in tumors.
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1 | BACKGROUND
The Skp, Cullin, F-box containing complex (SCF) type multi-subunit E3
ligase is the largest family of ubiquitin ligases, which facilitate the
turnover of approximately 20% of all ubiquitin-proteasomal system
(UPS)-regulated proteins in the mammalian system, including those
critically involved in tumorigenesis. The SCF family of ubiquitin ligases
(SCFCdc4) was first studied in budding yeast (Saccharomyces
cerevisiae) by using the in vitro reconstitution technique. Thereafter,
its complete structure was deciphered, and SCF was found to be a
variable complex made up of S-phase kinase-associated protein
1 (Skp-1), Cullins, F-box proteins, and RBX/ROC RING finger proteins
(Figure 1). Cullins act as a scaffold and comprises sequences that bind
Skp-1 and F-box proteins at its N-terminus and the RING proteins at
its C-terminus. The RING protein family consists of only two evolu-
tionary conserved members, RBX1 (RING box protein 1), also known
as ROC1 (regulator of Cullins), and RBX2/ROC2 (also known as SAG
[sensitive to apoptosis gene]) that are necessary for driving the cata-
lytic activity of SCF. F-box proteins are the most critical element of
the SCF assembly that is tasked with defining the substrate specificity
of the SCF complex. The mammalian genome comprises 69 F-box
proteins that include the WD40 domain-containing FBXWs, leucine-
rich repeats-containing FBXLs and FBXOs (made up of diverse
domains), and 7 Cullins (Cul-1, 2, 3, 4A, 4B, 5, and 7). FBXW7 is the
most widely studied F-box protein due to its role in a panel of both
normal and malignant cellular processes. FBXW7 binds to Skp1 and
Cullins through its F-box domain, and to the substrates through
WD40 or leucine-rich domains. Overall, Cullins-RBX/ROC acts as the
core of the SCF complex where RBX binds to ubiquitin-conjugating
enzymes (E2) and moderate the ubiquitin transfer from E2 to F-box-
targeted substrates. The activity of SCF E3 ligases is also driven by
events such as Cullin neddylation that disturbs the inhibitory binding
of Cullin by Cullin-associated NEDD8-dissociated protein 1 (CAND1).
Altogether, Cullin-based SCF assembly can be divided into four cate-
gories, Cul1-Skp1-F-box, Cul2/5-Elongins-B/C-VHL/SOCS box,
Cul3-BTB, and Cul4A/B-DDB1-DWD, thereby making SCF the largest
family of E3 ligases.1-3
FBXW7 (F-box with seven tandem WD40; also known as Fbw7,
Sel-10, hCdc4, hAgo, or Archipelago), encoded by the gene FBXW7
(loci, 4q31q.3), was first isolated as Cdc4 in budding yeast. The gene
comprises 4 untranslated regions (UTRs) and 13 coding exons, which
altogether define the substrate specificity of FBXW7, primarily
2 of 23 KAR ET AL.
through alternate splicing mechanisms. The human FBXW7 gene is
reportedly deleted in approximately 30% of all cancer types, thereby
underscoring its role in tumor progression and prognosis. Mammalian
cells express three FBXW7 isoforms, FBXW7α, FBXW7β, and
FBXW7γ, and each of these isoforms is localized in a tissue-specific
manner to restrict their interaction to specific substrates. Broadly,
FBXW7α is found in abundance in the nucleoplasm, as compared to
FBXW7β, which is cytoplasmic and FBXW7γ that is nucleolar.
FBXW7α is the most abundant isoform that facilitates the degradation
of most FBXW7-associated substrates. Furthermore, FBXW7α is
ubiquitously expressed in a range of proliferating cells and tumor
types and is capable of performing almost all the known functions of
FBXW7. On the other hand, FBXW7β helps in protecting the cells
from damaging events like oxidative stress (OS). These isoforms can
be structurally distinguished based upon their N-terminal region (NTR)
sequences and shared conserved domain sequences in their C-
terminal region (CTR). Nevertheless, all of these FBXW7 isoforms
comprise three essential domains, the dimerization domain, the F-box
domain, and 7-8 tandem WD40 repeats. The F-box domain helps in
binding FBXW7 to the Skp1 component of the SCF complex, and
together, the dimerization and WD40 repeat domain (harboring three
arginine residues); facilitate the FBXW7 binding to phosphorylated
substrates for SCF-mediated proteasomal degradation. Primarily, sub-
strate recognition happens through recognition of conserved
phosphorylated glycogen synthase kinase 3 (GSK3)-mediated domain
called the Cdc4 phosphodegrons (CPDs).4,5 Activated GSK3 phos-
phorylates the CPDs present in target substrates, which subsequently
bind to the WD40 repeats of FBXW7. GSK3-mediated phosphoryla-
tion of CPD is an essential step in the interaction between the sub-
strate and FBXW7, although the role of other kinases in the process is
now being explored. Mutations within the CPD motif have been
observed in several cancers that lead to the stabilization of oncogenic
substrates, like c-Myc and NOTCH. Sequence analysis of FBXW7 sub-
strates has identified the conserved CDP motif to be ΦXΦΦΦ-T/S-
PPX-S/T/E, where Φ is a hydrophobic residue and X could be any
amino acid. It must be noted that the phosphorylation of S/T/E resi-
due triggers the GSK3-mediated phosphorylation of T/S residue.
Some reports suggest the existence of more than one CPD motif
within FBXW7 substrates, like Cyclin E that comprise two CPD
motifs, one located in the T380 position, and the other being centered
around T62. Together, these two CPD motifs improve the efficiency
of FBXW7 binding with Cyclin E in response to various signaling
cues.6 Some studies highlight the antagonistic behavior of FBXW7α
and FBXW7β toward substrates. For instance, peroxisome
proliferator-activated receptor-gamma co-activator (PGC)-1α, a tran-
scriptional co-activator with widespread effects on cellular energy
metabolism undergoes different fate under FBXW7α and FBXW7β,
respectively. Cellular PGC-1α is downregulated by FBXW7β while
F IGURE 1 Domain architecture of E3 ubiquitin ligase and SCF-type E3 ligase complex: A, common architecture underlies E3 ubiquitin ligase
complex that mediate the targeted degradation of many cellular proteins. In targeting substrate proteins for degradation, ubiquitin is passed from
an E1 ubiquitin-activating enzyme to an E2 ubiquitin-conjugating enzyme to the protein substrate, with the final step (ligating ubiquitin to the
substrate) catalyzed by an E3 ubiquitin ligase. B, The SCF complexes are known to be E3 ligases and each complex in SCF-type E3 ligase interacts
with a set of adapter proteins that recruit different binding partners through specific protein-protein interaction domains such as WD40 repeats
and Leucine-rich repeats (LRR) and facilitate substrates for proteasomal degradation. This figure was created by an author (N.K.J.) using the
website https://app.biorender.com
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FBXW7α upregulates it through a ubiquitin-mediated stabilization.7-9
Overall, the biology of FBXW7 is very complex not only in normal
cells but in a wide range of carcinomas as well. It is therefore essential
to understand the FBXW7 based interactions with much more clarity
to identify disease-critical interactions, which potentially drive patho-
genesis in cancer patients.
The effect of E3 ligases on the NOTCH pathway is well known.
Members of several E3 ligase families interact either directly or indi-
rectly with NOTCH and with other NOTCH pathway-associated pro-
teins to facilitate a panel of cellular processes. Therefore, subtle
deregulation in the UPS, including the E3 ligases, coupled with
NOTCH-based aberrations can disturb normal cellular homeostasis
and may drive the cell to a malignant fate. For example, conditional
inactivation of Mind bomb-1 (Mib1), a ubiquitin ligase mostly associ-
ated with the endocytosis of Delta receptor in the mouse brain,
results in the complete loss of NOTCH activity, thereby hampering
neural stem cell differentiation. Likewise, Drosophila Su(dx), a member
of the homologous to E6-associated protein C terminus (HECT) family
of ubiquitin ligases is known to negatively regulate the NOTCH
pathway. Even further, the mammalian ortholog of Su(dx), Itch (atro-
phin-interacting protein 4), has been known to facilitate the poly-
ubiquitination of the membrane-anchored form of NOTCH, leading to
its lysosomal degradation.10-12 Several studies have confirmed that
the NOTCH intracellular domain (NICD) is the principal target of deg-
radation by the SCF family E3 ligases FBXW7 (Figure 2). An initial
study on Sel-10 (nematode homolog of FBXW7) found that NICD is
negatively regulated by FBXW7, which results in deactivation of the
NOTCH pathway. Over the last decade or so, NOTCH and FBXW7
mutations have been reported in a wide range of tumors, such as
pediatric and adult T-cell acute leukemia (T-ALL), diffuse large B-cell
F IGURE 2 NOTCH Pathway and FBXW7-dependant degradation of NOTCH intracellular domain (NICD). NECD, Notch extracellular domain;
EGFR, epidermal growth factor receptor; JICD, JAGGED1 intracellular domain; CSL, CBF1, Suppressor of Hairless, Lag-1; Co-R, co-repressor; Co-
A, co-activator; MAM, Mastermind-like (MAML) transcriptional co-activators. This figure was created by an author (N.K.J.) using the website
https://app.biorender.com
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lymphoma (DLBCL), splenic marginal zone lymphoma (SMZL), Hajdu-
Cheney syndrome, breast cancer (BC), non-small-cell lung carcinomas
(NSCLCs), etc. Given the array of pathological events, which may be
driven by a deregulated FBXW7-NOTCH interactome in tumors, it is
imperative to understand such disease-critical interactions with a
therapeutic perspective in mind.13
2 | KEY INTERACTIONS BETWEEN FBXW7
AND NOTCH PATHWAY ASSOCIATED
COMPONENTS
Although NICD remains the principal substrate of FBXW7 with
respect to the NOTCH pathway, there are emerging evidences that
highlight the interaction between FBXW7 and other accessory
proteins that are directly or indirectly involved in various key cellular
processes and in the discharge of NOTCH signaling duties (Table 1
and Figure 2). This section presents an insight into such novel interac-
tions involving FBXW7 and proteins, such as Presenilins (PS), Hes-1,
Hes-5, etc.
2.1 | Presenilins
Presenilins (PS) are the catalytic components of the enzyme
γ-secretase that is needed for NOTCH pathway activation. It has been
suggested that FBXW7α positively regulates the activity of NICD and
epidermal growth factor receptor (EGFR), principally by striking a bal-
ance between ubiquitylation and stability of both NICD and EGFR. PS
also negatively regulates FBXW7 transcriptional activity, thereby
TABLE 1 List of interacting components of FBXW7 and NOTCH and their associated functions in various key cellular processes
Key processes Interacting components Functions References
Keratinocyte development
and Skin tumorigenesis
FBXW7, NOTCH, and c-
Myc
FBXW7 regulates the proliferation and differentiation of keratinocytes,
and exerts both inhibitory and stimulatory signals during skin
carcinogenesis, primarily by counteracting the proliferation-advancing
activity of c-Myc and the tumor-suppressive activity of NOTCH.
14
Intestinal homeostasis FBXW7, NOTCH, Jun,
and DEK
FBXW7 mutation leads to accumulation of multiple substrates and results
in improper degradation of NOTCH, Jun, and DEK, which can




FBXW7 and NOTCH FBXW7 helps minimize NOTCH activation during zebrafish neural
development, thereby limiting the number of oligodendrocyte
progenitor cells (OPCs).
16
Melanoma FBXW7 and NOTCH FBXW7 as a critical tumor suppressor that is reportedly mutated and





FBXW7 and NOTCH FBXW7 does not operate as an onco-suppressor in MEFs. Rather, it
facilitates cell cycle progression and cell survival through degradation
of NOTCH1 by a FBXW7-dependant mechanism.
18
Angiogenesis FBXW7 and NOTCH FBXW7 is a positive regulator of angiogenesis that restricts the activity
of NOTCH in the endothelium of the growing vasculature.
19
Lipid Metabolism FBXW7 and RBP-J FBXW7 plays key roles along with NOTCH cofactor RBP-J in modulating







Hdac1 regulates the differentiation of LPCs into hepatocytes via Sox9b,
and into BECs through Cdk8, FBXW7, and NOTCH3 in zebrafish
models.
21
Neural cell differentiation FBXW7, NOTCH, and c-
Jun
FBXW7 regulates neurogenesis by antagonizing NOTCH and c-Jun N-
terminal kinase (JNK)/c-Jun pathway.
22
Osteoporosis FBXW7 and NOTCH Overexpression of NOTCH2 carrying a truncated C terminus that
escapes FBXW7-mediated degradation results in sustained osteoclast
activity.
23




FBXW7β transcription by NOTCH signaling provides an essential
mechanism that is coupled to and absolutely essential for the correct
specification of cell fates triggered by lateral inhibition.
24




SNCA promotes degradation of NOTCH1 intracellular domain (NICD) by
FBXW7-dependant mechanism, and attenuates the interaction
between NICD and RBP-Jk.
25
EGFR signaling and cell
transformation
FBXW7, NOTCH, and PS PS plays a key role during epidermal growth and transformation by
reciprocally modulating the EGFR and NOTCH signaling through
FBXW7.
26
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positively and negatively controlling EGFR and NOTCH pathway,
respectively. Researchers utilizing a novel epidermal conditional PS-
deficient mice (PS deactivation in keratinocytes of the basal layer of
the epidermis) reported epidermal hyperplasia in rodents along with
upregulation of EGFR and FBXW7 expression and downregulation of
NICD in keratinocytes. These observations emphasize on the fact that
FBXW7 can act as a central mediator of the upstream PS and the
downstream EGFR and NOTCH pathways.27Incidentally, EGFR and
NOTCH signaling pathways have opposing roles during epidermal dif-
ferentiation and tumorigenesis and PS plays a fundamental role in the
process. Loss of PS activity results in enhanced EGFR-dependent sig-
naling and cellular proliferation that drives oncogenic transformation
in mice, which can be directly attributed to the γ-secretase-
independent transcriptional upregulation of FBXW7. Moreover,
FBXW7α that tags NICD for degradation also can facilitate the posi-
tive EGFR activity by controlling the ubiquitination step necessary for
constitutive degradation and stability of EGFR. Furthermore, loss of
PS function in fibroblasts and primary keratinocytes results in FBXW7
overexpression and subsequent degradation of its substrates, such as
c-Jun and NOTCH1/4. Collectively, these findings propose a novel
role of PS during epidermal growth and transformation, essentially
involving an FBXW7-mediated reciprocal regulation of the EGFR and
NOTCH signaling cascades. However, it must be noted that the PS-
dependent regulation of FBXW7 and EGFR is totally independent of
its proteolytic activity as inhibition of γ-secretase has been found to
have no effect on the expression and activity of both FBXW7 and
EGFR. Interestingly, these findings differ from the well-established
hypothesis that FBXW7 by default acts as a tumor suppressor in sev-
eral cancers including epithelial tumors. This recent study is the first
of its kind to propose a crosstalk involving PS, EGFR, NOTCH, and
FBXW7 in skin cancers.26
2.2 | Hes-1 and Hes-5
Overexpression of NOTCH target genes has been reported in a range
of human cancers. Hes-1 and Hes-5 are known downstream effectors
of NOTCH signaling and their expression levels are highly upregulated
in a range of cancer types. Due to their deregulated expression
patterns, both Hes-1 and Hes-5 have been explored as potential diag-
nostic markers in patients with advanced-stage tumors. A recent
study by Sancho et al. found that Hes-5 directly represses the tran-
scriptional activation of FBXW7β. Notably, the study highlighted the
existence of a FBXW7β/NICD/Hes-5 positive feedback loop that
underlies FBXW7 haploinsufficiency in tumors.28 The existence of a
similar feedback regulatory loop was confirmed by another research
group that reported that FBXW7(Δ/+) heterozygous mice display
haploinsufficiency for NOTCH degradation that invokes intestinal
progenitor cell and neural stem cell differentiation. The potential
involvement of Hes-5 was attested by the fact that concomitant inhi-
bition of Hes-5 improved phenotypes and restores the order of nor-
mal stem cell differentiation. FBXW7 itself is transcriptionally
downregulated by the NOTCH downstream effector Hes-5, and
therefore, the perturbation of the feedback regulatory loop may be
held responsible for the FBXW7 haploinsufficiency as seen for
NOTCH-dependent functions in the cancer stem cells (CSCs). Collec-
tively, these observations reveal the non-unidirectional nature of the
functional relationship between FBXW7β and NICD, and the potential
existence of a double-negative, that is, positive feedback loop involv-
ing Hes-5. However, it remains to be seen whether Hes-1 participates
in the feedback loop, and in what capacity.24
2.3 | NUMB
NUMB was originally reported to be essential for cell fate determina-
tion during the neuroblast division. However, very recently, NUMB
was designated as a bonafide tumor suppressor gene in several human
carcinomas. For instance, in breast tumors, frequent loss of NUMB
activity has been observed that can be related to poor prognosis. Like-
wise, NUMB activity has also been found to be downregulated in
NSCLCs. Moreover, NUMB deletions and low NUMB expression
levels have also been reported in pro-neural glioblastomas. NUMB
protein regulates a panel of signaling pathways, such as p53, NOTCH,
and Hedgehog, and hence plays a key role during tumorigenesis. Stud-
ies have suggested that NUMB can bind to and represses the E3
ubiquitin ligase Mdm2, which is responsible for p53 degradation, con-
sequently leading to an upregulation in cellular p53 levels. Moreover,
NUMB can bind to the E3 ligase Itch that leads to the ubiquitination
of NOTCH, suggesting that NUMB may act as a connecting link
between NOTCH and Itch. It must be noted that NUMB itself serves
as a substrate for several E3 ligases, like seven in absentia homolog
1 (Siah-1) and ligand of Numb protein-X (LNX). Although little is
known about its interaction with FBXW7, a recent study found that
one of the predominant NUMB isoform, NUMB4, helps in FBXW7
ubiquitin ligase assembly formation and activation, thereby resulting
in enhanced NICD degradation and subsequent deactivation of the
NOTCH pathway. Nevertheless, the precise mechanism behind such
NUMB-based interaction is still unknown and a further in-depth
investigation is required to understand the pathological contribution
of NUMB4-mediated control of FBXW7 and NOTCH signaling during
carcinogenesis.28
2.4 | JAGGED-1
Not enough data are available to link the NOTCH pathway associated
ligand JAGGED1 with FBXW7. After the initial ligand-receptor inter-
action; NOTCH signaling is activated by a proteolytic cleavage of the
NOTCH receptor. JAGGED1 undergoes a similar γ-secretase-
mediated proteolytic cleavage that releases an intracellular fragment,
JAGGED1 intracellular domain (JICD). JICD can block NOTCH1 sig-
naling activation by decreasing the stability of the NICD. Moreover,
the presence of JICD prevents the formation of the NICD-RBP-Jk-
Mastermind complex and also expedites the proteasomal degradation
of NICD through the FBXW7-dependent pathway. Altogether, these
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early findings suggest that JICD can operate as a negative regulator of
NOTCH signaling by promoting the FBXW7-mediated degradation of
NICD. However, the precise mechanism behind such degradation and
the exact role of JICD and other NOTCH ligands in facilitating the
process remains an open area for further research.29
3 | MUTATIONAL EVENTS DRIVING
NOTCH AND/OR FBXW7 DEREGULATION IN
DIFFERENT CANCER TYPES
Perturbed genotypes in cancer can now be studied using whole-
genome sequencing of diverse tumor tissues and the observed gene
mutations can be further used for prognosis and classification of can-
cer subtypes. Although mutations in few disease-drivers can be
directly associated with key signaling pathway aberrations, a more
comprehensive understanding of how proto-oncogenes and tumor
suppressors drive oncogenesis in humans is much more difficult to
assess. Mutations have been reported widely in both NOTCH and
FBXW7, and have been associated with aberrant activation of the
NOTCH pathway and associated sequelae (Figure 3). The general
observation is that NOTCH mutations result in the constitutive activa-
tion of the pathway, while FBXW7 mutations impair its normal func-
tionality and results in the abnormal degradation of substrates,
including NOTCH, c-Myc, and c-Jun. However, it is essential to deci-
pher the precise mechanism by which these mutations can drive prog-
nosis in patients. In the underlying sections, we present an extensive
analysis of all these observed mutations including their prognostic rel-
evance in different cancer forms.
3.1 | T-cell acute lymphoblastic leukemia
Precursor T-cell acute lymphoblastic leukemia (T-ALL) continues to
remain a roadblock in pediatric oncology. T-ALL tumor relapses
display extremely poor prognosis, and therefore, it is vital to isolate
molecular risk factors, which allow early and efficient treatment strati-
fication. Activating mutations in the NOTCH gene indicates a poor
prognosis in T-ALL patients who can be attributed in part to the inac-
tivation of FBXW7, which possibly synergize with NOTCH1 receptor
activation. But, in some T-ALL cases, the pathological effect of
FBXW7 inactivation has been found to be separable from NOTCH1
activation, by not synergizing with activating NOTCH1 mutations,
while presenting a more favorable long-term outcome. NOTCH1
mutations have been reported in approximately 50% of human T-
ALLs, and missense mutations in FBXW7 have been reported in
approximately 15% of T-ALL cases. Mostly mutations in FBXW7 are
localized in the evolutionary conserved side of the gene, and both the
location and conservation statuses indicate that the novel missense
mutations may affect FBXW7 substrate targeting. Furthermore, it has
been reported that T-ALL patients, expressing NOTCH1/FBXW7 dou-
ble mutations, display a much favorable prognosis when compared to
patients with mutations in either NOTCH1 or FBXW7. Nevertheless,
the precise mechanism behind the separability of NOTCH1 receptor
activation and FBXW7 inactivation remains an open question at this
point. But, to an extent, this can be explained by the fact that activa-
tion of the NOTCH1 receptor is less pleiotropic than the inactivation
of its negative regulator FBXW7, because FBXW7 not only interferes
with the NOTCH pathway but also with a panel of other oncogenic
pathways and proteins, such as Cyclin E1, PS1, c-Myc, c-Jun,
Aurora-A, sterol regulatory element-binding protein (SREBP), etc.30,31
The majority of NOTCH mutations observed in T-ALLs belong to two
major classes: point mutations that destabilize the NOTCH1
heterodimerization (HD) domain, thereby enhancing its cleavage by
γ-secretase; and disruption/deletion mutations of the C-terminal PEST
(proline, glutamic acid, serine, and threonine) domain, which drive
NICD stabilization, thereby leading to the constitutive activation of
the NOTCH1 cascade. It has been reported that when mutations are
located at both HD and PEST sites, they are essentially in the cis loci
of the NOTCH1 allele. FBXW7 mutations can be attributed to
F IGURE 3 NOTCH signaling and
FBXW7 deregulation in different cancer
types. This figure was created by an
author (N.K.J.) using the website https://
app.biorender.com
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NOTCH1 HD mutations, suggesting that NOTCH pathway activation
is one of their major roles in T-cell leukemogenesis. Interestingly,
FBXW7 mutations are rarely detected alongside a PEST mutation and
it can be conferred that both FBXW7 and PEST mutations increase
the stability of the N1-ICD and therefore, may be functionally
redundant.32,33
Increased NOTCH or decreased FBXW7 expression can be asso-
ciated with a favorable outcome in pediatric T-ALLs. Recently, both
the frequency and prognostic manifestation of mutations in NOTCH1
and FBXW7 were investigated in patients of Swedish childhood T-
ALL treated according to the Nordic Society of Pediatric Hematology
and Oncology (NOPHO) ALL-1992 and ALL-2000 protocols. In a sub-
group of patients, the functional relevance of NOTCH1 mutations
was measured as a function of Hes-1, c-Myb, and c-Myc expression.
It was found that approximately 59% of the studied cases expressed
mutations in NOTCH1 and/or FBXW7. Incidentally, no such differ-
ence was observed in overall or event-free survival (EFS) in patients
with T-ALL expressing mutations in NOTCH or FBXW7 when com-
pared to those without any mutations. Moreover, T-ALL cells carrying
NOTCH1 mutations displayed high Hes-1 and c-Myb transcriptional
activity when compared to cells expressing wild-type NOTCH1,
thereby suggesting a hyperactivation of the NOTCH pathway. How-
ever, high Hes-1 expression improved overall EFS in some cases, for
which the mechanism remains to be studied further.34 Another study
group extended the previously established Childhood Acute Lympho-
blastic Leukemia (CoALL) protocol to a wider cohort and additionally
included the Argentine T-ALL patients from ALL IC-BFM (Berlin-
Frankfurt-Münster) protocol to potentially study novel mutations. The
study revealed a stronger discriminatory effect on the genotype/phe-
notype relationship concerning early treatment response and long-
term outcome. Overall, it was found that approximately 60% of T-ALL
samples expressed at least one NOTCH1 mutation, and a few of them
displayed both NOTCH1 and FBXW7 mutations. A very small fraction
of the cohort displayed only FBXW7 mutations, while close to 30% of
the cohort presented a wild-type configuration of either gene. Inter-
estingly, four new NOTCH1 mutations were identified in the C-
terminal PEST domain, in the rarely affected Lin12-NOTCH (LNR)
domain, and in the ankyrin repeat domain. These novel LNR mutations
may provide a more comprehensive insight into the structure of the
NOTCH1 negative regulatory region (NRR) and the R1946 mutation,
identified in the ankyrin domain may serve as an unusual loss-of-
function mutation. Furthermore, the more common HD and PEST
domain mutations might individually exert distinct functional effects
on the cellular homeostasis with prognostic implications.35 HD
domain mutations drive subunit dissociation or trigger NOTCH1 to
become sensitive to ligand-independent cleavage, thereby resulting in
increased NICD stabilization and translocation to the nucleus. HD
mutations like L1575P limit the efficiency of furin-mediated cleavage
and induce the γ-secretase-dependent NOTCH1 activation. HD
domain mutations are known to drive a substantial change in second-
ary structure of NOTCH by a non-conservative amino acid substitu-
tion. Although this region is known to harbor most of the activating
NOTCH mutations, it cannot be ignored that some of these may
actually represent polymorphism. The PEST domain, which is located
in the C-terminal part of NOTCH1, regulates protein turnover and
deletions in the PEST region can increase the stability of the protein,
which results in upregulation of the NOTCH1 cascade. R465C and
R479Q mutations in the conserved protein-protein interaction
domains of FBXW7 abrogate NOTCH1 binding that can lead to con-
stitutive activation of NOTCH1. Interestingly, FBXW7 mutations have
been mostly linked with the HD domain that causes signal amplifica-
tion, whereas FBXW7 mutations in PEST region sequences are less
common. Till date, there is no concrete evidence to suggest the pres-
ence of mutations both in the PEST domain and in the FBXW7 gene.
Nevertheless, some research groups argue that mutations in the PEST
domain could be a means to relieve mutational pressure on the
FBXW7 gene.31 Study conducted on patients with adult T-ALL
treated on the United Kingdom Acute Lymphoblastic Leukaemia XII
(UKALLXII)/Eastern Cooperative Oncology Group (ECOG), E2993
protocol found a notable positive correlation between a NOTCH1
mutation in the HD domain only and an FBXW7 mutation, and a
strong negative correlation between NOTCH1-PEST mutation and
FBXW7 mutation. These data are consistent with an earlier study that
reported that NOTCH1-HD and FBXW7 mutations act in unison, sim-
ilar to dual HD and PEST mutations. In spite of the fact that FBXW7
also targets c-Myc for degradation, the relationship observed in this
current study highlight the fact that FBXW7 mutations are acquired
by T-ALL cells to improve NOTCH1 signal strength. It must be noted
that if FBXW7 mutations were expressed by tumor cells predomi-
nantly to upregulate c-Myc activity and therefore, they are likely be
detected in conjunction with PEST mutations, at least in some cases.
Quite astonishingly, the current study found that NOTCH1/FBXW7
MUT and WT groups were equally balanced in terms of percentages
of standard- and high-risk patients, thereby implying a more discrete
role of mutations in driving prognosis of T-ALL.36
Lastly, in a few T-ALL cases, mutations have been reported in the
IKAROS gene, which can be associated directly or indirectly to
NOTCH and/or FBXW7 aberrations. In mouse, T-ALL-activating
NOTCH1 mutations usually collide with loss-of-function mutations in
Ikzf1 gene that encodes the zinc-finger transcription factor IKAROS
that regulate hematopoietic stem cell functions and drive lineage fate
decisions of early hematopoietic progenitors. Therefore, IKAROS
dominant-negative mice lack B-cells, natural killer (NK) cells, and fetal
T cells, and postnatally synthesize aberrant, clonally expanded T cells.
Moreover, aggressive T-cell carcinomas are observed in mice carrying
the dominant-negative or hypomorphic IKAROS alleles, suggesting a
decisive role of the protein in T-lineage tumor suppression. Inciden-
tally, approximately 60 to 70% of all T-ALLs originating in IKAROS
germline mutant mice models display NOTCH1 mutations, such as
PEST and/or HD domain mutations found in human T-ALL. Beverly
and Capobianco first proposed that IKAROS directly antagonizes
NOTCH1 target gene activation, and also found that retroviral expres-
sion of the full-length IKAROS isoform, Ik1, leads to cell cycle arrest
that can be attributed to the downregulation of the canonical NOTCH
target gene, Hes-1. IKAROS binds to the Hes-1 promoter and com-
petes with RBPJ at Hes-1 promoter sequences to repress
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NOTCH1-mediated reporter gene expression. While these observa-
tions do indicate that IKAROS suppresses the NOTCH1 activation
and subsequent transcription of downstream target genes like Hes-1
in thymocytes, the precise role of FBXW7 mutations in these
IKAROS-mediated processes needs to be investigated further in T-
ALL tumors.27,37
3.2 | Adult T-cell leukemia
Adult T-cell leukemia (ATL) is an aggressive lymphoproliferative dis-
ease with an extremely poor prognosis. Several study groups have
earlier reported the presence of NOTCH1 activating mutations and
constitutive activation of the pathway in patients suffering from acute
ATL but less is known about the FBXW7 mutations and their effect in
ATL. Yeh et al. reported high frequency of FBXW7/hCDC4 mutations
within the WD40 substrate-binding domain in ATL cells. FBXW7 is a
well-known tumor suppressor that limits tumor cell proliferation,
thereby supporting the absolute necessity for its inactivation in pro-
gressive tumors. Two FBXW7 mutants, D510E and D527G were
found in ATL tumors, which retained their unique ability to target nor-
mal FBXW7 substrates, such as endogenous Cyclin E, MCL-1, and c-
Myc. However, these mutants lost their ability to facilitate degrada-
tion of N1-ICD in these ATL cell lines. These observations are in stark
contrast with earlier studies where FBXW7 mutants have been found
to abolish the degradation of all its substrates, including N1-ICD. Fur-
ther investigation revealed that D510E mutant retains the ability to
interact with N1-ICD but is ineffective in facilitating the
K48-mediated ubiquitination of N1-ICD. Although this could be a pos-
sible explanation behind selective degradation of N1-ICD by these
FBXW7 mutants, the complete rationale underlying D510E and
D527G oncogenic activity in ATL still remains elusive. Interestingly,
this study strongly advocates the existence of a crosstalk between
mutated FBXW7 and several other proteins in ATL cell lines, such as
viral oncogene (HTLV-I Tax), p53, c-Myc, etc. Given the high rate of
mutation in both p53 and c-Myc in human carcinomas, selective loss
of FBXW7 functions may play a more decisive role in the oncogenic
process. Furthermore, FBXW7 mutations in ATL tumors may create a
window of opportunity for targeted anticancer therapies. For
instance, combinatorial therapy using the drug Imatinib along with
siRNA-mediated FBXW7 inactivation in mice has been found to drive
the depletion of leukemia-initiating cells when compared to normal
hematopoietic stem cells.38
3.3 | Sézary syndrome
Sezary syndrome (SS) was first identified in 1938 and is also known as
“the red man syndrome” or '1' homme rouge'. SS is a cutaneous T-cell
lymphoma in which CD4+ tumor cells also known as Sézary cells are
localized in the skin, lymph nodes, and peripheral blood. Clinically, this
disease has often been misdiagnosed and managed as chronic derma-
titis or psoriasiform lesion. Although SS can be treated with low-dose
prednisone and chlorambucil or by using immunomodulating proto-
cols, the prognosis remains extremely poor with a median survival
between 2 and 4 years post-diagnosis and disease-specific 5-year sur-
vival of about 15 to 20%. New treatment modalities, which utilize
histone-deacetylase (HDAc) inhibitors along with allogeneic stem cell
transplantation, are now being explored to treat SS cases. Over the
years, various mechanisms have been proposed with respect to con-
stitutive NOTCH1 signaling activation in SS cells, including activating
mutations in the NOTCH1 gene. Sequence analysis of the HD region
(exon 26) and PEST region (exon 34) of the NOTCH1 along with the
entire coding region of the FBXW7 revealed the absence of any kind
of mutations in the HD and PEST domain region of NOTCH1 and/or
FBXW7, suggesting that other regulatory mechanisms might be in
operation in SS. This is in sharp contrast to what is normally observed
in ALL cases where aberrant activation of NOTCH1 is mostly linked
to mutations in the HD and PEST domain, or mutations in FBXW7,
which impair ubiquitination and proteasomal degradation of N1-ICD
protein. Incidentally, the current study reported no specific mutation
within the phosphatase and tensin homolog (PTEN) that is again in
contrast with an earlier report that found instances of heterozygous
deletion within PTEN, albeit in limited SS cases. Altogether, these
observations indicate the presence of a complicated interactome
involving NOTCH, FBXW7, and PTEN in SS cells that warrant further
investigation.39,40
3.4 | Squamous-cell cancer of the head and neck
Squamous cell carcinoma of the head and neck (SCCHN) is one of the
most common cancer types worldwide and accounts for more than
500,000 new cases and close to 4000,000 deaths per year. SCCHN
depicts a heterogeneous disease entity with a range of etiological fac-
tors attributed to the pathogenesis of distinct molecular subsets of
tumors, which display distinct biological and clinical features. Apart
from the well-known risk factors such as tobacco smoking and alcohol
consumption, infection with human papillomavirus (HPV) has now
become more critical to understand the epidemiology and prognosis
of SCCHN. Most SCCHN cases are diagnosed with locally advanced
disease states, which often warrant multimodal treatment strategies.
Despite significant improvements in radiation and surgical techniques
and the use of chemotherapy and monoclonal antibody protocols in
the advanced stage of the disease, more than half of all patients expe-
rience a relapse with extremely poor prognosis, not suitable for treat-
ment options with curative intention. Nevertheless, the treatment of
SCCHN is expected to change in the future as targeted therapies con-
tinue to be explored. Recently, a next-generation sequencing study
conducted on SCCHN specimens revealed a previously unknown
insight into the molecular pathogenesis of the disease. The study
unraveled novel mutations affecting genes involved in the differentia-
tion program of squamous epithelium, especially in the NOTCH/p63
axis, such as NOTCH1, TP63, and FBXW7. The most remarkable find-
ing emerged from the whole-exome sequencing studies was the high
incidence of loss-of-function mutations in the NOTCH1 gene. It was
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observed that the majority of these NOTCH1 mutations in SCCHN
were missense mutations, which were localized at or close to identi-
fied important receptor domains such as the ligand-binding domain
(EGF repeats 11, 12, and 13) or the ankyrin region. Moreover, the
detected nonsense mutations were found to result in truncated
NOTCH1 proteins lacking domains required for transcriptional activ-
ity. These available data imply that NOTCH1, owing to certain muta-
tional events, may act as a tumor suppressor in head and neck
epithelium. It was further observed that p63 downregulation by
NOTCH decreased the ability of NOTCH to limit growth and differen-
tiation along with antagonistic effects on Hes/HERP family members,
like Hes-1, Hey-1, and Hey-2. p63 has been reported to modulate the
expression of the JAGGED1 and/or 2, thereby assisting NOTCH in
expanding its signaling effects to adjacent cells. It appears from the
current study that there exists a complex negative feedback loop
between NOTCH and p63 that may regulate the balance between
self-renewal and differentiation. Given the negative control of
FBXW7 on the NOTCH pathway, it will be interesting to further
investigate the FBXW7/NOTCH/p63 axis in SCCHN.41,42
3.5 | Esophageal squamous cell carcinoma
Esophageal squamous cell carcinoma (ESCC) is viewed widely as a
serious malignancy with respect to prognosis and mortality rate.
Esophageal carcinoma is the eighth most common cancer worldwide
in terms of incidence, and sixth most in terms of cancer-related deaths
worldwide with developing nations making up more than 70% of total
cases and deaths. Despite numerous advances in diagnosis and treat-
ment, the 5-year survival rate for all patients diagnosed with esopha-
geal cancer is abysmal. A recent study performed exome sequencing
on tumor-normal pairs that revealed non-silent mutations both in
tumor tissues and cell lines. Genes involved in cell cycle and apoptosis
administration were found to be mutated by somatic alterations of
tumor protein 53 (TP53), cyclin D1 (CCND1), cyclin-dependent kinase
inhibitor 2A (CDKN2A), nuclear factor erythroid 2-related factor
2 (NFE2L2), and retinoblastoma transcriptional corepressor 1 (RB1) in
almost 99% of studied cases. Moreover, histone modifier genes,
including KMT2D (also called MLL2), histone methyltransferase 2C
(KMT2C), lysine demethylase 6A (KDM6A), EP300, and CREBBP were
found to be mutated. Even further, the Hippo and NOTCH pathways
were found to be dysregulated and could be attributed to mutations
in AJUBA, FAT1, FAT2, FAT3, or FAT4, and NOTCH1, NOTCH2 or
NOTCH3 or FBXW7. Altogether, these findings present the muta-
tional landscape of ESCC and highlight mutations as key epigenetic
modulators with prognostic and potentially therapeutic
implications.43,44
3.6 | Adenoid cystic carcinoma
Adenoid cystic carcinoma (ACC) is a malignant neoplasm arising from
salivary glands of head and neck region. This type of tumor was first
described as a benign neoplasm and was named cylindroma owing to
the cribriform appearance formed by tumor cells with cylindrical
pseudo spaces. Approximately 12 to 15% of all salivary gland tumors
are ACCs, which are more common in minor salivary glands and the
submandibular gland and less common in the sublingual and parotid
glands. ACC is a very rare tumor of the head and neck that accounts
for less than 1% of all head and neck cancers. Currently, ACC, espe-
cially of the trachea lacks well-characterized diagnostic markers and
there is no specific therapy available against metastatic ACC of the
trachea. Genomic mutations have been reported in the NOTCH path-
way that has been investigated in order to determine the efficacy of
NOTCH inhibitor in ACC of the trachea. For instance, gain-of-function
mutations of the NOTCH1 gene were found to be quite frequent that
leads to stabilization of the N1-ICD. Furthermore, NOTCH2,
NOTCH4, JAGGED1, and FBXW7 mutations have also been identi-
fied in some ACC cases. Incidentally, the observed NOTCH mutation
can be associated with solid subtype and shorter overall survival but
cannot be considered as an independent prognostic factor in the pres-
ence of several histologic subtypes. Nonetheless, NOTCH and
FBXW7 mutations can be studied further to examine the pathogene-
sis and prognosis of ACCs.45,46
3.7 | Melanoma
Melanoma is a malignant neoplasm of the melanocytes. Melanocytes
are cells embedded in the basal layer of the epidermis that produces
the pigment melanin, responsible for skin color. As one among the
three major forms of skin cancer, with basal cell carcinoma and squa-
mous cell carcinoma being the other two, melanoma has the worst
prognosis, resulting in the vast majority of skin cancer-related mortal-
ities. Given the high mortality rates, a greater understanding of the
molecular pathogenesis and disease-critical interactions of malignant
melanoma is urgently required. FBXW7 has been found to be mostly
inactivated in melanoma that results in constitutive NOTCH1 activa-
tion. And therefore, FBXW7 mutations may be considered as a
“driver” genetic event in malignant melanoma. A recent study utilized
an exome sequencing screen to characterize the functional impact of
FBXW7 mutations in melanoma, and highlight its substrate NOTCH1
as a suitable therapeutic marker in the clinical setting. shRNA
(shRNA1 and shRNA2)-mediated silencing of FBXW7 using lentiviral
transduction of melan-a melanocytes expressing mutant NRAS
(NRASG12D) was found to result in statistically significant
upregulation of the NOTCH1 downstream target protein Hey1, with
increasing levels observed post-MG-132 treatment. Furthermore, the
decrease in FBXW7 transcriptional activity was found to promote
tumor angiogenesis, observed through enhanced expression of angio-
genic driver proteins, including NOTCH1. Based on these findings, it
can be said that FBXW7 mutational inactivation represents a potent
mechanism for constitutive NOTCH1 activation in melanoma. Addi-
tionally, the present study found NOTCH1, c-Myc, and Cyclin E to be
consistently regulated by FBXW7 in melanoma as opposed to Aurora
A (inconsistent) and myeloid cell leukemia sequence-1 (MCL1)
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(unregulated). Taken together, the current study offers an interesting
avenue for anti-NOTCH treatment strategies in melanoma as well as
an understanding of the spectrum of genomic alterations represented
within the melanoma tumors, which can be used for stratifying
patients for treatment based on these aberrations.17,47
3.8 | Osteochondromas
Osteochondromas are normally bone protuberances surrounded by a
cartilage layer that tends to affect the extremities of the long bones in
an immature skeleton and deform them. They normally occur singly
but multiple forms of presentation may also be seen in certain cases.
Osteochondromas have a very typical appearance and are easily diag-
nosed but an atypical site (in the axial skeleton) and/or malignant
transformation of the lesion may sometimes make it challenging to
identify osteochondromas immediately using radiographic techniques.
There exists a continuing debate on whether osteochondroma is actu-
ally a developmental disorder (pseudotumoral lesion) or neoplasm.
Nevertheless, irrespective of whether it is a pseudotumoral lesion or a
more common benign bone tumor, it is definitely an exostosis phe-
nomenon (external bone proliferation that deforms the bone). Exo-
stosin glycosyltransferase 1 (EXT1), an endoplasmic reticulum
transmembrane protein that frequently mutated in multiple
osteochondromas, acts as a connector between NOTCH1 and
FBXW7. Interaction between NOTCH1 and FBXW7 has been found
to be significantly enhanced in the presence of EXT1. Moreover,
N1-ICD level has been found to be significantly reduced in the pres-
ence of EXT1. Interestingly, the reduced N1-ICD levels in the pres-
ence of EXT1 were found to be dependent on FBXW7. As a matter of
fact, there are about 479 identified mRNAs that are co-regulated by
both EXT1 and FBXW7, which incidentally represent more than 30%
of all FBXW7 substrates. It is possible that EXT1 is functionally associ-
ated with FBXW7, presumably through priming kinases and substrates
like N1-ICD and therefore, mutational events affecting the EXT1 or
FBXW7 gene can significantly affect the pathogenesis in
osteochondroma patients through the NOTCH pathway.48,49
4 | INTERACTION BETWEEN ENZYMES
MODULATING PHOSPHORYLATION
RELATED EVENTS, FBXW7 AND NOTCH
4.1 | Kinase
Targeted inhibition of the NICD, which is an essential component of
the NOTCH pathway, is now widely being explored as a novel strat-
egy for treating a wide range of cancer. The activity or stability of
NICD is driven by numerous protein-protein interactions and post-
translational modifications (PTMs), such as ubiquitination, phosphory-
lation, etc. Among all these interactions, NOTCH ubiquitination and
degradation by FBXW7 is considered to be one of the most relevant.
As mentioned earlier, FBXW7 directly binds NICD to facilitate its
ubiquitination and subsequent proteasomal degradation. These
FBXW7-mediated processes essentially require phosphorylation at
Thr-2512 residue of the NICD. Until now, only two kinases were
known to phosphorylate NOTCH1 at Thr-2512, namely the
homeodomain-interacting protein kinase 2 (HIPK2) and mitogen-
activated protein/ERK kinase kinases1 (MEKK1). Recently, dual-
specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2), a
Ser/Thr kinase was reported to play a major role in the regulation of
cellular proliferation, differentiation, and survival. DYRK2 was found
to interact with a panel of signaling pathways through the phosphory-
lation of specific proteins, such as eIF2Bε, CRMP4, 4E-BP1, NFAT,
p53 tau, hPXR, c-Jun, c-Myc, GSK, Snail, katanin, and Siah2. DYRK2
aberrations have been reported in the development and progression
of several human carcinomas, such as esophageal adenocarcinoma,
breast cancer, non-small cell lung cancer, ovarian serous adenocarci-
noma, etc. DYRK2 has been shown to limit epithelial-mesenchymal
transition (EMT) by degrading Snail in ovarian cancer and its knock-
down promotes tumor growth and invasion, thereby attesting its role
as a tumor suppressor. Furthermore, in response to genotoxic stress,
the protein ataxia-telangiectasia mutated (ATM) has been shown to
phosphorylate and stabilize DYRK2 that in turn phosphorylates p53 at
Ser46, thereby driving cellular apoptosis. DYRK2 has also been
reported to act as an upstream negative regulator of the NOTCH
pathway that is highly active in several cancers. DYRK2 can directly
associate and phosphorylates the NICD at Thr-2512, thereby facilitat-
ing its proteasomal degradation, driven by the E3 ligase FBXW7. RAM
domain together with the protein MAML1 helps co-localize NICD and
CBF1, Suppressor of Hairless, Lag-1 (CSL) in order to activate the
transcription of NOTCH downstream target genes. These reports sug-
gest that the RAM domain plays a key role in promoting the interac-
tion between N1-ICD and DYRK2 and therefore, DYRK2 modulation
by chemotherapeutic agents may have a strong effect on the viability,
motility, migration, and invasion capacity of carcinomas expressing
NOTCH1.50
Another key positive regulator serum/glucocorticoid-inducible
kinase 1 (SGK1) has been identified to interact with NOTCH through
FBXW7. SGK1 is a vital regulator of an array of cellular processes,
including metabolism, channel conductance, cell volume, differentia-
tion, proliferation, and survival. SGK has a very close sequence iden-
tity with the catalytic domain of Akt and with the phosphorylated
serine and threonine residues that rest in the RxRxx[S/T] motif. SGK1
is regulated in a phosphoinositide 3-kinase (PI3K)-dependent fashion
in response to insulin or growth factor signaling. Once activated,
SGK1 phosphorylates an array of substrates, such as GSK-3β, b-Raf,
IKKβ, FKHRL1, Nedd4-2, p27, Fe65, and SEK1. SGK1 also acts as an
inhibitor of γ-secretase enzyme that is necessary for NOTCH1 path-
way activation. A recent study by Mo et al. found that N1-ICD is able
to associate in a trimeric complex along with FBXW7 and SGK,
suggesting that SGK1 may facilitate the degradation of N1-ICD
through an FBXW7-dependent mechanism. In fact, activated SGK1
assists in decreasing N1-ICD stability by activating FBXW7 through
phosphorylation at serine 227 position. Accumulated dexamethasone
in cells can activate SGK1 that in turn activates FBXW7 through
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serine phosphorylation as mentioned. In line with this observation,
both the mRNA and protein level expression of N1-ICD has been
found to be enhanced in SGK1-deficient cells when compared to
SGK1 wild-type cells. Collectively these results show that the kinase
SGK1 can inhibit the NOTCH1 signaling by hastening the degradation
of N1-ICD by FBXW7. However, till date, the mechanism by which
SGK1 controls the anti-leukemic effect of glucocorticoids has
remained unknown and for that reason the SGK1/FBXW7/N1-ICD
trimeric complex may represent a potential therapeutic target for
improving the efficiency of anti-leukemic therapies in T-ALL tumors
expressing NOTCH1.51
It must be noted that FBXW7 explicitly recognizes phosphory-
lated substrates. GSK-3β is a key kinase involved in the FBXW7 path-
way. There is enough data to suggest that the sequences identified by
FBXW7 in c-Myc, c-Jun, and SREBP1a or -1c are actually phosphory-
lated by GSK-3β, which drives the ubiquitylation and degradation of
these substrates through the FBXW7 pathway. Although N1-ICD is
known to be phosphorylated by GSK-3β, the repression of endoge-
nous GSK-3β activity in mammalian cells surprisingly does not
increase but rather decreases the stability of N1-ICD. Moreover,
genetic investigations in Drosophila have found GSK-3β homolog
Shaggy to be involved in the positive regulation of the NOTCH signal-
ing cascade. These observations indicate that GSK-3β-mediated phos-
phorylation of N1-ICD may not necessarily trigger its recognition and
degradation by FBXW7. A very recent study identified a NOTCH pho-
sphodegron that was somewhat different from the “standard” pho-
sphodegrons of c-Myc and Cyclin E. Interestingly, the serine or
threonine residue at position +4 corresponding to the central threo-
nine was replaced with glutamic acid in the NOTCH phosphodegron
motif. This subtle difference in the N1-ICD phosphodegron motif may
be responsible for driving the GSK3-mediated kinase activities,
thereby regulating diverse cellular processes in a cell type- or develop-
mental stage-specific manner.18,52
4.2 | Phosphatase
Serine/threonine/tyrosine interacting protein (STYX), a protein
belonging to the tyrosine phosphatases (PTPs) family, is by basic func-
tionality a pseudophosphatase. Pseudophosphatases carry mutations
within their active site signature motif (HCX5R) that makes them inac-
tive. They resemble substrate trapping mutants, essentially PTPs
mutated to bind their substrates, as “wild type” substrate binding
mutants. Although pseudophosphatases preserve the three-
dimensional fold and their ability to bind phosphorylated proteins,
however, in comparison to PTPs, pseudophosphatases can't dephos-
phorylate the phosphorylated protein during cellular processes. STYX
has a diffused expression in various tissues but not much is known
about its biological role in cancers. STYX has been associated with cell
proliferation, migration, invasion, and apoptosis in colorectal cancer
cells and a range of studies have indicated that STYX acts as a latent
oncogene that inhibits apoptosis in colorectal and breast cancer,
mainly by binding to FBXW7. In breast cancer cells, STYX has been
found to suppress FBXW7 expression through direct protein-protein
binding. Furthermore, in endometrial cancer (EC) cells, STYX has been
found to interact with FBXW7 in regulating the NOTCH and mTOR
signaling pathway. In endometrial tumors, aberrant activation of the
NOTCH cascade has been associated with increased cell proliferation,
and suppression of the mTOR pathway has been found to repress
tumor initiation and progression. A recent study found that FBXW7
regulates the proliferation and apoptosis of EC cells by initially
suppressing the NOTCH signaling linked protein and p-mTOR/mTOR,
and subsequently the NOTCH/mTOR signaling pathway. Interestingly,
in EC cells overexpressing FBXW7, STYX was found to directly inter-
act with FBXW7 and also assisted in balancing the FBXW7 expression
levels. Consistent with this observation, FBXW7 overexpression was
found to promote proliferation and limit apoptosis of EC cells in a
STYX-dependant fashion, and the deployment of NOTCH activator
JAGGED1 together with mTOR activator MHY1485 reversed the
function of overexpression of FBXW7 in the context of cell prolifera-
tion and apoptosis. Furthermore, the NOTCH inhibitor DAPT was
found to reverse the function of the overexpression of STYX. Collec-
tively, these observations indicate that the STYX/FBXW7 axis is
involved in the development of EC cells and may be involved in the
development of other tumors as well through the regulation of
NOTCH-mTOR signaling pathway. And therefore, STYX being active
in several cancers, its role in modulating the NOTCH-mTOR interac-
tion through FBXW7 warrants further attention.53,54
4.3 | Peptidyl-prolyl cis-trans isomerase
Prolyl-isomerase (Pin1) is the only recognized peptidyl-prolyl cis-trans
isomerase (PPIase) that explicitly recognizes and isomerizes the phos-
phorylated Serine/Threonine-Proline (pSer/Thr-Pro) motif. In other
words, Pin1 catalyzes the cis/trans conversion of specific motifs
found in certain proteins, thereby triggering a conformational change
necessary for the complete activity and crosstalk of a range of signal-
ing pathways. Pin1 has been attributed to multiple cellular processes,
the aberration of which can result in both degenerative and neoplastic
outcomes. Pin1 is highly expressed in the bulk of cancers and its inhi-
bition has been found to significantly repress cancer progression.
Recently, Pin1 was found to be essential for sustained NOTCH
activity in breast cancer cells irrespective of FBXW7α status. In fact,
isomerization triggered by interaction with Pin1 was held accountable
for the recognition and degradation of N1- and N4-ICD by FBXW7α
in a PP2A-dependent fashion. These observed interactions between
Pin1 and NOTCH1/4 is extremely relevant in modulating the NOTCH
paralog-driven functions in breast tumors. NOTCH4 is an essential
modulator of basal breast cancer stem cell (BCSCs) population, while
NOTCH1 activity is more limited to luminal precursors both in the
normal mammary gland as well as in breast tumors. The recent find-
ings now place Pin1 as a key facilitator of stage-specific physiological
and pathological NOTCH functions in the breast epithelial compart-
ment. FBXW7α has been implicated in the maintenance of normal
neural, colon, and hematopoietic stem cells primarily through the
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degradation of NICD. This study shows that FBXW7 acts as a key
negative driver acting against the proliferation of the BCSCs compart-
ment, through the degradation of N1- and N4-ICD, thereby
preventing BCSC self-renewal and metastasis in vivo. Nevertheless,
the role of Pin1 is extremely significant in maintaining high levels of
N1-ICD and N4-ICD, irrespective of FBXW7α expression. Based on
these observations, it is therefore likely that aberrant expression or
activity of Pin1 may strongly diminish the selective pressure for acti-
vating NOTCH or FBXW7α mutations.55,56
5 | NOTCH AND FBXW7-BASED
DEREGULATIONS IN MODULATING KEY
ONCOGENIC PROCESSES
5.1 | Cell cycle, differentiation, and proliferation
Deregulation of the cell cycle, which is a characteristic feature of
oncogenic transformation, promotes genetic instability and drives
abnormal cell proliferation. In the past decade, the domain of cancer
genetics has shown that hyperactivating mutations in embryonic sig-
naling networks, such as NOTCH, Wnt, and Shh, coupled with loss of
function of tumor suppressor proteins drive malignant transformation
of a range of tumors. Gene expression profiling of these complicated
and redundant mitogenic processes to recognize prognostic signa-
tures and their therapeutic targeting have proved challenging to the
core. The cell cycle that acts as an integration point for an array of
information cascaded through the upstream signaling pathways
depicts a viable target for diagnostic and therapeutic modalities. As a
result, analysis of the aberrant mitotic engine proteins and associated
deregulations in human carcinomas are now paving the way for the
identification of novel cell cycle-directed therapies. The mammalian
cell cycle is a highly organized and regulated mechanism that guaran-
tees perfect duplication of genetic material through cell division. This
subtly controlled regulation is contingent on growth-regulatory stimu-
lus as well as signals by proteins monitoring the genetic integrity to
ensure that there is not any genetic damage whatsoever. Carcinogen-
esis is characterized by aberrant cell cycle activity that leads to uncon-
trolled cell proliferation and subsequent deregulation of the apoptotic
machinery, thereby preventing normal cell death.57-59 In this section,
we present the recent advances made with respect to the role of
FBXW7 and NOTCH in driving aberrant cell cycle activity in tumors
that might be of therapeutic significance in identifying targeted
therapies.
FBXW7 mediates the ubiquitylation and sequential degradation
of proteins, such as Cyclin E, c-Myc, c-Jun, and NOTCH, which regu-
late cell cycle activity. As discussed earlier, a wide range of tumors
harbor loss-of-function mutations in the FBXW7 gene, which ulti-
mately result in the disproportionate accumulation of FBXW7 sub-
strates with carcinogenic outcomes. For instance, unexpected loss of
FBXW7 activity in mouse embryonic fibroblasts (MEFs) has been
reported to induce cell cycle arrest and prevent apoptosis, primarily
driven by abnormal aggregation of N1-ICD. Forced expression of
NICD1 reverses the phenotypes of FBXW7-deficient (FBXW7Δ/Δ)
MEFs with respect to cell cycle and apoptosis. A recent study found
that Rbpj deletion normalizes the aberrant cell cycle activity as seen in
FBXW7Δ/Δ MEFs, thereby attributing NOTCH1 signaling cascade in
the process. In contrast, the conditional inactivation of the p53 gene
(that operates largely as a transcription factor, and can trigger a vari-
ety of antiproliferative programs) was found to prevent cell cycle
arrest but did not trigger apoptosis in FBXW7Δ/Δ cells. Altogether,
these findings imply that FBXW7 may not directly function as an
onco-suppressor in MEFs, rather it plays a more supportive role in cell
cycle progression and cell survival, primarily through regulation of
N1-ICD. Furthermore, increased cell cycle activity and decreased apo-
ptosis as observed in FBXW7Δ/Δ MEFs can be attributed to NOTCH
hyperactivation, and p53 may be involved in the process, thereby sig-
nifying the pathological importance of FBXW7/NOTCH/p53 axis dur-
ing carcinogenesis.18,60 There are similar studies that enforce the
hypothesis that FBXW7/NOTCH/p53 axis may be crucial in driving
cell cycle-associated activities in tumors. In human hepatocellular car-
cinoma (HCC), RBP-J-interacting and tubulin-associated (RITA) has
been found to facilitate the nuclear export of RBP-J to tubulin fibers
that in turn downregulates NOTCH-mediated transcription. More-
over, RITA overexpression in HCC cell lines increases the expression
levels of p53 and FBXW7 while limiting the expression of key cell
cycle mediators, such as Cyclin D1, Cyclin E, Cdk2, Hes-1, and NF-κB
p65. These changes ultimately trigger G0/G1 cell cycle arrest, inhibit
growth, and promote apoptosis in SMMC7721 and HepG2 cell lines.
It can be understood that RITA exercises its tumor-suppressive effects
primarily through induction of G0/G1 cell cycle arrest and apoptosis,
thereby indicating the functional significance of the FBXW7/
NOTCH/p53 axis not only in HCC but possibly in other tumors as
well.61,62
Family with sequence similarity 83, member D (FAM83D) is a
microtubule-associated protein (MAP) with dynamic mitotic function
that has been found to be deregulated in several tumors. Predomi-
nantly, FAM83D localizes within the cytoplasm during interphase and
at spindle microtubules and poles during mitosis. FAM83D transcrip-
tion is upregulated and the protein phosphorylated upon the cell
entering the G2/M phase. FAM83D depletion in cells helps break the
chromosomes aggregation on the metaphase plate and on the nuclear
envelope breakdown (NEBD), thereby delaying the start of anaphase
during mitosis. FAM83D overexpression has been extensively
reported in primary tumors carrying TP53 mutations when compared
to those with wild-type TP53 gene. Together, these observations indi-
cate that FAM83D may have a key role to play during tumor cell
growth and proliferation, primarily by exerting its control on cell cycle
activity. A recent study investigated the role of FAM83D in human
colorectal cancer and found that FAM83D mRNA expression level
was significantly upregulated in tumor cells when compared to adja-
cent normal colon cells. Similar observations were reported in human
colorectal cancer cell lines, such as DLD-1, Caco-2, RKO, HT-29,
LoVo, SW480, and HCT116, where both FAM83D mRNA and protein
level expression were found to be upregulated, especially in SW480
and HCT116 lines. FAM83D knockdown in HCT116 and SW480 was
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found to be closely associated with decreased cell proliferation, col-
ony formation, migration and invasion, and increased apoptosis of
these cell lines. Interestingly, FAM83D knock-down also resulted in
the upregulation of FBXW7 and an expected downregulation of
N1-ICD. Introduction of FBXW7 siRNA completely reversed the sup-
pressive effect of FAM83D knockdown on NOTCH1, thereby
suggesting an important role of FAM83D in modulating NOTCH
activity through the E3 ligase, FBXW7. Moreover, forced NOTCH1
overexpression in FAM83D knockdown cells was found to have a pro-
found impact on the cell proliferation, migration, and invasion of
HCT116 and SW480 cell lines. Collectively, these pieces of evidence
suggest that FAM83D may be involved in the FBXW7/NOTCH1 deg-
radation pathway and therefore, may be explored as a molecular tar-
get for colorectal cancer diagnosis and treatment.63,64
FBXW7 has been found to modulate the differentiation and pro-
liferation of keratinocytes by facilitating the degradation of key pro-
teins like c-Myc and NOTCH. A recent study reported that
FBXW7-deficiency in keratinocytes increases the proliferative capac-
ity, mainly through the accumulation of c-Myc but not NOTCH. How-
ever, FBXW7 deficiency drives early differentiation of keratinocytes
in a manner that is dependent on both NOTCH and c-Myc. Although
FBXW7-deficient keratinocytes proliferate excessively in vitro, loss of
FBXW7 does not activate keratinocytes to differentiate into squa-
mous cell carcinoma (SCC) in vivo, triggered by the expression of
oncogenic Ras. A plausible explanation behind this could be that the
keratinocytes stem cell population becomes exhausted as a result of
heightened NOTCH activity. These interesting findings show that
FBXW7 may be involved in regulating proliferation and differentiation
of keratinocytes through inhibitory and stimulatory actions during skin
carcinogenesis. In fact, FBXW7 could be discharging two conflicting
duties during skin carcinogenesis by promoting or inhibiting tumor
formation through selective degradation of NOTCH and c-Myc,
respectively. As mentioned earlier, NOTCH accumulation in
FBXW7-deficient keratinocytes suppresses the tumor formation
driven by oncogenic H-Ras. In line with this, genetic suppression of
NOTCH activity coupled with activation of Ras in keratinocytes has
previously been shown to foster the development of aggressive SCC
that can be partially attributed to the rise in the expression levels of
proteins, such as MRCKα, ROCK1, and ROCK2, all of which operate
downstream of Rho-family GTPases. NOTCH1 downregulates the
expression of these kinases, and tumorigenesis is completely
abolished through their inhibition. In FBXW7-deficient keratinocytes,
the abundance of kinases, like MRCKα, ROCK1, and ROCK2, has been
found to be significantly downregulated. Moreover, forced deletion of
Rbpj reverses these effects and enhances tumor formation. Therefore,
it can be said that FBXW7 likely controls keratinocyte behavior by
modulating the NOTCH-dependent regulation of small-GTPase signal-
ing pathways. Given that the complex crosstalk between NOTCH and
multiple oncoproteins including c-Myc is a key determinant of homeo-
stasis in epithelial tissues, FBXW7 appears to be pivotal molecule
involved in the regulation of differentiation and proliferation of epi-
dermal stem cells and tumorigenesis in epithelial tissues. This hypoth-
esis may hold true for other types of tumor cells as well, excluding the
epithelial cohort. It can be conferred that reduced cell proliferation
due to overaccumulation of NOTCH and/or c-Myc in many tumor
types may involve selective degradation by FBXW7 in a tissue-
specific manner.14,27 Intestinal FBXW7 inactivation can induce
adenomas and its inactivation in intestinal cells has been found to
deregulate the NOTCH and Jun pathways, which affects the fate of
progenitor cells and proliferating crypt cells. DEK, a highly conserved
nuclear factor that is preferentially expressed in actively proliferating
and malignant cells, is a prime target of GSK-3β-mediated phosphory-
lation, and is responsible for switching the alternative RNA splicing of
tropomyosin (TPM) isoforms. FBXW7 inactivation prevents the degra-
dation of the DEK, which leads to selective loss of the epithelial iso-
form of TPM that along with NOTCH and c-Jun, drives carcinogenesis
in mice models. As would be expected, FBXW7 inactivation leads to
the upregulation of both NOTCH and c-Jun, which are FBXW7 sub-
strates. NOTCH signaling has been implicated in the regulation of cell
fate decisions, mainly through its downstream effector Hes-1.
Although some reports suggest that Hes-1 and Hes-5 both participate
in the NOTCH-mediated cell fate determination, evidence supporting
the role of Hes-5 is not conclusive enough. Nevertheless, over-
expression of Hes-1, and not Hes-5 in intestinal tumors, indicates that
these may be regulated by additional transcription factors and there-
fore, have overlapping yet discrete patterns of expression in the gut.
Hes-1, −6, and − 7 transcripts are mostly restricted to the crypt
region, while Hes-5-expressing cells have been reported in the villus
epithelium and the mesenchyme. Collectively, these observations sug-
gest that FBXW7 mutation can drive failed intestinal differentiation
and promote proliferation through NOTCH downstream effectors and
possibly DEK. Consistent with this paradigm, an intact and functional
FBXW7 may therefore restore homeostatic control mechanisms and
impair oncogenic activators by facilitating their steady degradation.
Therefore, therapeutic modalities based on the partial delivery of
FBXW7-α to intestinal tumor cells may limit nuclear DEK and
β-catenin accumulation and drive better prognosis in patients.15,65
5.2 | Apoptosis
Apoptosis is the mechanism of programmed cell death that is driven
by energy-dependent biochemical mechanisms and characterized by
distinct morphological features. It is an essential component of several
biological processes including normal cell turnover, hormone-
dependent atrophy, proper development, functioning of the immune
system, etc. Aberrant apoptotic mechanism (either too little or too
much) has been attributed in a range of human conditions, such as
neurodegeneration, ischemic injury, autoimmune disorders, and differ-
ent types of cancer. The distinct ability to regulate the life or death of
a cell is considered a modality with immense therapeutic potential.
Hence, research continues to focus on the identification and interpre-
tation of the cell cycle machinery and associated signaling cascades
that modulate cell cycle arrest and apoptosis. Although a panel of key
apoptotic proteins has been identified, the precise molecular mecha-
nisms of operation of these proteins remain a challenge. A wide range
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of anticancer therapies currently deployed in clinical oncology exploit
the unimpaired apoptotic signaling cascades to initiate cancer cell
death. Therefore, an aberration in the apoptotic pathways may drive
drug resistance in tumors, so limiting the effectiveness of therapies.
Accordingly, a greater understanding of the apoptotic cell death sig-
naling pathways and associated protein-protein interactions may aug-
ment the efficacy of cancer therapy and help in bypassing drug
resistance. Several proteins both pro-apoptotic and anti-apoptotic
participate in the cell death process, such as Bcl-2, Bcl-xL, p53, Mcl-1,
etc.66,67In addition to driving cell growth, proliferation, and differenti-
ation, overexpression of c-Jun, c-Myc, or NOTCH can also trigger
programmed cell death or apoptosis. However, uncertainty surrounds
around how FBXW7-deficient cells elude apoptosis in a setting with
upregulated c-Jun, c-Myc, and/or NOTCH levels. One study suggests
that FBXW7 regulates cellular apoptosis by targeting MCL1, a pro-
survival Bcl-2 family member for ubiquitylation and degradation in a
GSK3-dependent manner. Human T-ALL cell lines display a close
association between FBXW7 deficiency and MCL1 overexpression
and therefore, T-ALL cell lines with defective or inactive FBXW7 are
resistant to Bcl-2 antagonist ABT-737 but are sensitive to the multi-
kinase inhibitor, Sorafenib. FBXW7 activation or MCL1 deregulation
has been found to revive the sensitivity of T-ALL cell to ABT-737,
thereby positioning MCL1 as a therapeutically important bypass sur-
vival protein that empowers FBXW7-deficient cells to evade apopto-
sis. Furthermore, there are studies that have found a direct interaction
between NOTCH and MCL1 in the regulation of programmed cell
death. For instance, NOTCH1 and NOTCH2 signaling are constitu-
tively activated in chronic lymphocytic leukemia (CLL) tumors, and
inhibition of NOTCH1 and NOTCH2 has been found to enhance apo-
ptosis in CLL cells, which is accompanied by downregulation of MCL1
and upregulation of IL4. A limited set of studies argue that MCL1
downregulation by NOTCH may not be due to decreased transcrip-
tion or degeneration by caspases but due to enhanced degradation
through a FBXW7-dependent process. Collectively, these findings
position FBXW7, NOTCH, and MCL1 as key drivers of apoptosis.68,69
5.3 | Metastasis
Metastasis remains a major concern and a principal cause of death in
cancer patients. Therefore, elucidation of the genes and mechanisms
that control this process has remained an area of active research.
Metastasis essentially involves a complex array of a process that
begins with the detachment of cancer cells from a primary tumor
followed by their migration to neighboring tissue, entry into the circu-
latory system, and finally, invasion into distant organs to form second-
ary tumors. As discussed extensively, FBXW7 mutations are frequent
in T-ALL (31%) and cholangiocarcinoma (35%). A majority of these
studied mutations are missense in nature and a result of amino acid
substitutions at key arginine residues such as Arg465 and Arg479 in
the WD40 region of FBXW7. Several studies have found FBXW7
deregulation in the host environment as one of the key determinants
of cancer metastasis. For instance, Yumimoto et al. characterized the
mechanism underlying metastasis of bone marrow stromal cells
(BMSCs) and found that FBXW7 deletion results in NOTCH accumu-
lation and subsequent activation of the protein CCL2. In fact, CCL2
expression in FBXW7-deficient cells overexpressing NOTCH drives
the formation of metastatic niches through the localization of Mono-
cytic Myeloid-Derived Suppressor Cells (Mo-MDSC). Therefore, inhi-
bition of the CCL2/CCR2 pathway limits the metastatic incidence
observed in FBXW7-deficient mice. CCL2 has also been attributed in
the recruitment of monocytes/macrophages to sites of pulmonary
metastasis in mice with breast tumors. CCL2 is mainly expressed by
BMSCs, along with other cells facilitating tumor metastasis such as
bone marrow-derived dendritic cells (BMDCs), fibroblasts, endothelial
cells, smooth muscle cells, etc. These observations suggest that the
interaction between FBXW7, NOTCH, and CCL2 can be a crucial
driver event of cancer metastasis. Moreover, identification of FBXW7
and NOTCH as upstream regulators of CCL2 expression provides an
insight into the mechanism by which the production of this chemokine
is regulated. This potentially could be a basis for the development of
new treatment strategies aiming to target the metastatic phenomenon
in tumors.70,71
Alpha-synuclein (α-synuclein or SNCA), a soluble presynaptic pro-
tein belonging to the synuclein protein family, is known to form insolu-
ble fibril aggregates, which play a very important role in the
pathogenesis of Parkinson's disease (PD), however, its precise role in
carcinogenesis is not clearly understood. Studies have found that
α-synuclein is abundantly expressed in primary and metastatic melano-
mas but remain largely untraceable in normal skin and non-melanocytic
cutaneous carcinoma. This can hold true for other metastatic carcino-
mas as well, such as brain tumors where α-synuclein is expressed hand-
somely when compared to benign meningiomas. α-synuclein can
differentially modulate the production of melanin in melanoma and
dopaminergic neuronal cells, thereby affecting cell susceptibility to
ultraviolet radiation-induced injury. Nevertheless, the pathological rele-
vance of α-synuclein during the malignant progression of carcinomas is
still being investigated. A recent study reported a previously unknown
function of SNCA in facilitating the degradation of N1-ICD through the
FBXW7 pathway. Principally, SNCA represses NOTCH1 transcription
at the genetic level and also limits the interaction between N1-ICD and
RBP-Jk. Moreover, both exogenous and endogenous SNCA down-
regulates N1-ICD protein levels in tumors mainly through the
proteasomal pathway rather than the lysosomal pathway, thereby
suggesting that SNCA might be serving as a connecting link between
FBXW7 and N1-ICD. There are studies that support this hypothesis
and have found SNCA to directly interact with FBXW7. Altogether,
given the abundance of SNCA in metastatic melanomas and possibly in
other tumors, these findings indicate that SNCA may be a key regulator
of metastasis through the FBXW7/NOTCH axis.25,72
5.4 | Other miscellaneous key oncogenic events
Notch hyperactivation may be caused by mutations of NOTCH-
associated genes, altered upstream key oncogenic events, or
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microenvironment signals. Cancer cells may exploit this aberrant sig-
naling to “educate” the surrounding microenvironment cells toward a
pro-tumoral behavior. For instance, in context to tumor microenviron-
ment (TME), it has been observed that epithelial NOTCH1 signaling
drives metastasis in serrated colorectal cancer (CRC), where poor-
prognosis of CRC subtypes CMS4/CRIS-B are controlled by NOTCH1.
Furthermore, TGF-β-mediated neutrophil infiltration has been found
critical for NOTCH1-driven metastasis, although neutrophil targeting
provides therapeutic opportunity in metastatic CRC. In addition,
NOTCH1 signaling can be activated via mutation of FBXW7, found in
11% of human CRCs. Thus, epithelial NOTCH signaling rewires the
TME of CRC to drive poor-prognosis subtypes and metastasis.73
Recently, the role(s) of NOTCH signaling in T-cell antitumor immunity
and TCR- and chimeric antigen receptor-based immunotherapies has
been reported. NOTCH signaling is required for optimal T-cell-
mediated antitumor immunity. Consequently, tumor cells and the
TME have acquired mechanisms to suppress NOTCH signaling to
evade T-cell-mediated killing. Tumor-mediated suppression of
NOTCH signaling in T-cells can be overcome by systemic administra-
tion of NOTCH agonistic antibodies and ligands or proteasome inhibi-
tors, resulting in sustained NOTCH signaling and T-cell activation. In
addition, NOTCH receptors and ligands are being used to ameliorate
the generation and specificity of T-cells for adoptive transplant immu-
notherapies.74 Based on these few evidences, it is concluded that
NOTCH and FBXW7 directly or indirectly involve in cancer metabo-
lism, where TME and immune cells play a significant role.
6 | MULTIPLE DRUG RESISTANCE (MDR),
FBXW7, AND NOTCH IN TUMORS
Multidrug resistance (MDR) phenomenon is observed against many
effective anticancer drugs and remains a challenge in therapeutic
oncology. MDR can develop due to various biological mechanisms,
such as activation of detoxifying systems, increased drug efflux and
decreased drug uptake, activation of DNA repair mechanisms, evasion
of drug-induced cell death, etc. Although tremendous progress has
been made to understand the precise MDR mechanisms in vitro, the
transfer of this knowledge to the clinical setting has not been met
with much success. Hence, identifying genes and pathways crucial to
the development of MDR in vivo and subsequently establishing reli-
able protocols for analyzing clinical samples can help design targeted
therapies to bypass it. Drug activation in vivo involves intricate mecha-
nisms during which drug molecules interact with a host of proteins.
These interactions can degrade, modify, or orient the drugs with other
proteins and pathways, eventually leading to their activation in vivo.
Many anticancer drug molecules inevitably must undergo this type of
metabolic activation to achieve pure clinical efficacy. Nevertheless,
cancer cells over a period of time can develop resistance to such drug
molecules and limit their activation. For instance, cytarabine (AraC), a
nucleoside drug that is used in the treatment of acute myelogenous
leukemia (AML), gets activated after multiple phosphorylation events
to transform into AraC-triphosphate. However, genetic mutations or
deregulations of proteins in the activation pathway can limit the acti-
vation of AraC, thereby leading to AraC resistance. Several proteins
and a panel of associated pathways have been implicated in MDR,
such as cytochrome P450 (CYP) system, glutathione-S-transferase
(GST) superfamily, uridine diphospho-glucuronosyltransferase (UGT),
etc.75,76 Several studies have implicated both NOTCH and FBXW7 in
the MDR process. The expulsion of CSCs or EMT type cells, which are
typically drug-resistant, is extremely crucial as these are deemed to be
the “root cause” of tumor relapse. NOTCH regulates the fate of CSCs
and contributes to the acquisition of the EMT phenotype that is
involved in driving the MDR phenomenon in a subset of tumors.
FBXW7 inactivation has been shown to promote resistance in tumors
against certain anti-tubulin chemotherapeutic agents. Moreover, loss
of FBXW7 has been found to be a key prognostic factor promoting
resistance to gamma-secretase inhibitors (GSIs) in certain cancer
types. These encouraging reports suggest that targeting NOTCH
and/or FBXW7 may be used as a strategy for overcoming MDR. In
the subsequent sections, we highlight the biological significance of
NOTCH and FBXW7 deregulation in promoting MDR in tumors.4,77,78
6.1 | GSI resistance in tumors
GSIs block NOTCH activation and therefore, present an attractive
therapeutic modality for tumors with hyperactive NOTCH signaling.
Despite the promise, several tumors become resistant to GSIs over a
period of time and continue to grow normally post-treatment. Some
studies have reported FBXW7 mutations in GSI-resistant tumors,
which lead to constitutive activation of the NOTCH pathway. For
instance, FBXW7 mutations in T-ALL tissues may give rise to
dominant-negative FBXW7 alleles, which hamper NICD degradation
through the proteasomal pathway. Although FBXW7 mutations may
confer resistance to GSIs, NOTCH-PEST domain truncations in T-ALL
tumors essentially do not have the same effect. One suitable explana-
tion can be that in T-ALL tumors with PEST mutations, only one allele
is affected by the heterozygous mutations while the other allele con-
tinues to encode an intact NOTCH. Therefore, increased NOTCH
activity arising out of these single-allele PEST mutations may not be
alone sufficient to drive resistance against GSIs. However, FBXW7
double mutations completely block FBXW7 activity, thereby providing
a free hand to NOTCH, c-Myc, and several other substrates in facili-
tating the T-ALL resistance against GSIs. c-Myc being a downstream
target of the NOTCH pathway, it may be possible to overcome GSI
resistance in T-ALL tumors by combining GSIs with compounds that
block c-Myc activity. Recently, TMPyP4, a cationic porphyrin that
binds to and stabilizes guanine quadruplexes in DNA was found to
have beneficial effects when combined with GSIs. Incidentally, c-Myc
harbors a promoter sequence that can form a guanine quadruplex and
TMPyP4 is able to bind and restrict c-Myc transcription and further
prevent the growth of tumor cells in vivo. Therefore, compounds like
TMPyP4 may be beneficial in combination with GSIs to overcome
drug resistance in patients expressing FBXW7 double mutations.79,80
miRNAs have also been implicated in promoting GSI resistance in
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T-ALL tumors through an interaction with both NOTCH and FBXW7.
Notably, the NOTCH-mediated activation of miR-223 transcription
has been found to represses the tumor-suppressive effects of FBXW7
in T-ALL cell lines. miR-223 promoter harbors a conserved RBPjk
binding site that is nested within an NF-kB consensus sequence,
thereby suggesting that both NOTCH and NF-kB act cooperatively to
provide regulatory signals to control miR-223 transcriptional activity.
In line with this observation, NOTCH1, NOTCH3, and p65 have all
been found to be directly recruited to the miR-223 promoter site.
Therefore, in T-ALL cells, NF-kB inhibition has been found to limit the
expression of endogenous miR-223. Consistent with this, the abroga-
tion of the NF-kB pathway in Jurkat IKKγ−/− cells along with low
NOTCH1 and NOTCH3 levels results in the downregulation of miR-
223 mRNA levels. Interestingly, ectopic modulation of miR-223
expression was found to limit T-ALL resistance to GSI treatment.
Upregulated miR-223 driven GSI resistance has been attributed in
part to FBXW7 and as the data suggest, resistance in Molt3 and
Jurkat T-ALL cells may be due to GSI-induced increased C/EBPα
expression that leads to a completed loss in FBXW7 activity. Alto-
gether, these observations indicate that specific inhibition of miR-223
may help restore GSI sensitivity in GSI-resistant T-ALL cells carrying
wild-type FBXW7 and therefore, can be explored as an attractive
targeted therapy for GSI-resistant T-ALLs harboring wt FBXW7 and
overexpressing miR-223.81
6.2 | Resistance to chemotherapeutic agents other
than GSIs
Prolyl-isomerase (Pin)-1 and NOTCH1 have been associated with
chemoresistance that is mostly driven by the activity of CSCs. In par-
ticular, NOTCH1 plays a key role in this process since it facilitates the
transcription of a panel of cell survival and drug efflux genes, such as
BIRC5, SURVIVIN, Bcl-2, ABCG2, etc. Therefore, it is very likely that
the regained sensitivity of CSCs to drug treatment observed both
in vitro and in vivo due to Pin1 downregulation may be a collaborative
result of impaired drug efflux and cell survival proteins, which are
under the direct control of NOTCH1. G3 aggressive and poorly differ-
entiated tumors are characterized by a large population of CSC over-
expressing both Pin-1 and NOTCH1 that may be responsible for drug
resistance by simply safeguarding the self-renewal and expansion of
the CSC pool. A very recent study found that Pin-1 not only plays a
key role in regulating the stability of various phosphoproteins, includ-
ing most FBXW7 substrates, but can also directly regulates the stabil-
ity and/or function of FBXW7 or any other F-box protein. Pin-1
interacts with FBXW7 in a phosphorylation-dependent manner and
facilitates its degradation by preventing the dimerization of FBXW7.
Pin-1 overexpression in tumors reduces FBXW7 levels and suppresses
the ability of FBXW7 to repress proliferation and oncogenic transfor-
mation. In contrast, Pin-1 deficiency leads to FBXW7 overexpression
that subsequently limits MCL-1 expression, thereby sensitizing the
tumor cells to drugs like Taxol. Although it is clear that Pin-1 can
mediate chemoresistance in tumors but it remains to be investigated
whether Pin-1 drives the process in CSCs only through the FBXW7/
NOTCH1-axis or by modulating other pathways as well.55,82
Lung cancer is the most common type of malignancy worldwide
and close to 80% of all lung cancers are categorized as NSCLC that
remains the principal cause of lung cancer-related mortalities. Several
signaling pathways have been attributed to play a key role in NSCLC
chemoresistance including NOTCH-1, JAK/STAT, PI3K/Akt, Wnt,
TGF-β, etc. There exists a strong correlation between FBXW7,
NOTCH, and miR-223 in mediating NSCLC resistance against the drug
erlotinib. FBXW7 is one of the principal targets of miR-223 and is well
known to play a key role in carcinogenesis by facilitating the degrada-
tion of various oncoproteins, which may be involved in MDR, such as
c-Myc, Cyclin-E, NOTCH, c-Jun, mTOR, MCL1, etc. Several studies
have earlier highlighted the role of miR-223 in regulating tumor cell
sensitivity to chemotherapeutic drugs, although its precise role in pro-
moting tumor resistance to the effects of epidermal growth factor
receptor tyrosine kinase inhibitors (EGFR-TKIs) used in the treatment
of NSCLC remains undeciphered. To answer this question, a recent
study investigated the pathological significance of miR-223 both in
the parental NSCLC cell line (HCC827) and erlotinib-resistant
HCC827 cell line (HCC827/ER). miR-223 expression was found to be
significantly upregulated in HCC827 cells when compared to
HCC827/ER cells. Furthermore, siRNA-mediated silencing of either
Akt or NOTCH and miR-223 expression results in decreased resis-
tance of HCC827/ER cells to erlotinib. On the contrary, forced miR-
223 overexpression expression triggers cell resistance in HCC827
cells to erlotinib, suggesting a very crucial role of miR-223 in modulat-
ing erlotinib response. Further investigation revealed that miR-223
promotes erlotinib resistance in NSCLC cell lines, primarily by down-
regulating FBXW7 expression, which subsequently results in
increased NOTCH activity in these cells. Moreover, FBXW7 over-
expression reverses the observed phenotype and limits the erlotinib
resistance in HCC827/ER cells. Collectively, these observations sug-
gest that NSCLC cells upregulate miR-223 to facilitate erlotinib resis-
tance in NSCLC cell lines, primarily through the FBXW7/NOTCH
pathway. Therefore, the miR-223/FBXW7/NOTCH axis may outline a
promising therapeutic target for NSCLC patients whose neoplasms
are resistant to erlotinib. Further studies in patient-derived tumor
xenograft (PDX) animal models may be needed to reinforce that this
mechanism is indeed responsible for acquired resistance to erlotinib
in vivo.83
7 | FBXW7 AS A DIAGNOSTIC MARKER IN
TUMORS?
In simple terms, diagnostic markers are biochemical pointers to the
presence or progress of a disease. However, in a clinical setting, it
often refers to a protein that can be detected in plasma and body
fluids. Tumor markers are measurable biomolecules that can be attrib-
uted to a malignancy and are either secreted directly by cancer cells
(tumor-derived) or by the body as a whole in response to a tumor
(tumor-associated). Tumor markers may not be used as the primary
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means of cancer diagnosis, rather they can be used as an assay to sup-
port the diagnosis. Cancer is a group of diseases requiring alterations
in the homeostatic status and expression of a discreet array of genes
that confer a survival advantage and undiminished proliferative capa-
bility to somatic or germinal cells. Primarily, alterations in three princi-
pal classes of genes, namely (proto) oncogenes, tumor suppressor
genes, and DNA repair genes drive the formation of tumors, which
escape the natural and inherent apoptotic mechanism(s). Although
tumor diagnostic markers may be inconclusive as screening assays for
the detection of occult (hidden) cancers, once a particular tumor has
been located using a marker, the marker can be used as a means of
observing the success (or failure) of treatment. Furthermore, the
marker expression level may also reveal the extent (the stage) of the
disease, indicating how quickly the cancer is likely to spread and
thereby assist in framing treatment protocols.8 As discussed in great
detail, FBXW7 is the substrate recognition component of an evolu-
tionary conserved SCF-type E3 ubiquitin ligase that brings about the
degradation of several key proto-oncogenes, such as c-Myc, Cyclin E,
NOTCH, and c-Jun. Essentially, FBXW7 is itself a tumor suppressor,
the regulatory network of which is disturbed in many human carcino-
mas. Diverse cancer-associated mutations in FBXW7 and its sub-
strates have been observed, and loss of FBXW7 function has been
found to induce chromosomal instability during tumorigenesis.
FBXW7 displays a unique mutational spectrum in tumors, and differ-
ent types of mutations can drive substrate-specific consequences
including dominant-negative effects.84 The question that we ask here
is, can FBXW7 serve as a diagnostic marker in cancer, given its der-
egulated expression patterns in a range of tumors?
Several groups are mapping FBXW7 expression patterns in vivo in
tumors and emerging evidences are encouraging enough to suggest
that FBXW7 may be used as a diagnostic marker at least in some
forms of tumor. For instance, there are very few prognostic markers,
which can be relied upon to indicate the progression of gastrointesti-
nal stromal tumors (GISTs). GISTs are the most common mesenchymal
tumors of the gastrointestinal tract, which originate from the intersti-
tial cells of Cajal lineage due to activating mutations affecting c-Kit or
platelet-derived growth factor receptor alpha (PDGF). FBXW7 regu-
lates tumor size and tumor cell mitosis and hence plays a key role in
the progression of GISTs. In hepatocellular and colorectal carcinomas,
FBXW7 under-regulation affects c-Myc and NOTCH1 expression
levels, which can be directly correlated to cell proliferation, migration,
invasion, and hence poor prognosis. Koga et al. reported that FBXW7
expression may be a key etiological factor driving recurrence-free sur-
vival (RFS) in intermediate or high-risk patients, when compared to
expression levels of c-Myc, phosphorylated c-Myc, and NOTCH1 in
some tumor subsets. And therefore, FBXW7 may be explored as a
novel prognostic marker during GIST progression. However, there
may be certain limitations: First, FBXW7 mutations are frequent in
several cancer cells, while FBXW7 mutations associated with GISTs
are still being elucidated. Second, the precise molecular mechanism of
FBXW7 deregulation in GISTs remains unclear. Nevertheless, as
observed through multivariate analysis, FBXW7 expression in GISTs
may be investigated further as an independent predictive marker of
RFS following surgery in patients who shall benefit from adjuvant
therapy better than conventional risk stratification in a clinical envi-
ronment.85 Unfortunately, there are limited studies that have investi-
gated the prospect of using FBXW7 as diagnostic marker during GIST
progression in a large patient cohort. A recent study evaluated the
effectiveness of FBXW7 as a clinical marker in a cohort of gastric car-
cinoma (GC) patients on postoperative chemotherapy protocols. The
study found that gastric tumors expressing low levels of FBXW7 were
the ones responsible for metastatic progression and poor prognosis.
Furthermore, immunohistochemistry (IHC) analysis found that
FBXW7 overexpression could be strongly correlated to improved
response to chemotherapy. This opened a new avenue for research
where low FBXW7 expression patterns can be explored as a predic-
tive tool for poor prognosis in patients with GC. Besides, given the
range of chemotherapeutics reported in this large database study,
FBXW7 was found to serve as an important predictor of chemothera-
peutic responses. Nevertheless, more investigations might be
warranted to testify the effectiveness of FBXW7 as a diagnostic
marker during or post-chemotherapeutic regime, not only in GIST but
also during the progression of a wide range of cancers.86
High Tribbles homolog 2 (TRIB2) expressions can be associated in
part with NOTCH1 and/or FBXW7 mutations in pediatric T-ALL group,
although there are evidence for other drivers in operation. TRIB protein
family members encode pseudo-kinase proteins that are highly con-
served and function as adaptors in signaling activities for key cellular
processes. Reports demonstrate that TRIB2 knockdown can limit tumor
growth and proliferation and limit drug resistance in patients suffering
from human chronic myelogenous leukemia (CML), mainly through the
ERK/STAT3 pathway. Moreover, high TRIB2 expression correlates well
with increased NOTCH1 activity in some adult and pediatric T-ALL
cases. Interestingly, high TRIB2 expression alone may adequately distin-
guish a T cell profile among all subtypes of leukemia and therefore, may
act as potential marker for malignancies with T cell features. Lastly, the
interactions between TRIB2 and other T cell signaling pathways may be
useful in uniquely identifying leukemia subtypes and can further
advance our understanding of T-ALL pathology.87,88
8 | NOVEL THERAPEUTICS TARGETING
DEREGULATED NOTCH-FBXW7
INTERACTION IN TUMORS
Over the last decade, enormous progress has been in the field of can-
cer therapeutics in addition to the most common and conventional
therapies that include surgery, radiation, and chemotherapy. There are
drawbacks to these conventional therapeutic protocols, which cause a
lot of physical as well as psychological stress among infirm. Chemo-
therapeutic drugs trigger different types of toxicity in the patient's
body, including cardiotoxicity, hematotoxicity, neurotoxicity, gastroin-
testinal toxicity, hair follicle toxicity, nephrotoxicity, and many more.
Moreover, these drugs target rapidly multiplying cells and are some-
time unable to distinguish between normal cells and tumor cells,
thereby limiting their maximum allowable doses. On the contrary,
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these chemotherapeutic agents get swiftly eliminated through the
ADME mechanisms, and therefore, administration of a high dosage of
the drug is needed to circumvent rapid elimination and for widespread
distribution of the drug to the tumor area. Subsequent research
advancements have led to the identification of various alternative
modalities, such as immunotherapy, liposomal therapy, targeted ther-
apy, hormone therapy, and stem cell therapy, to mitigate the detri-
mental effects of these drugs. The use of biological molecules to
activate the immune system that is severely compromised in patients
has been an area of intense deliberation. In contrast to chemotherapy,
targeted use of biomolecules is highly efficient against tumor cells and
come with limited side effects. Therefore, targeted use of biological
and physiological therapies intending to reduce side effects and
increasing the long-lasting efficacy will be extremely beneficial in can-
cer treatment going forward.89,90 Deregulated FBXW7 and NOTCH
interactions can be targeted through novel biomolecules to improve
prognosis in tumors. For instance, Chromosome Maintenance Region
1 (CRM1) inhibition that can lead to nuclear retention of tumor sup-
pressor proteins has been explored as a therapeutic strategy in
pancreatic ductal adenocarcinoma (PDAC). It was found that CRM1
inhibitors exert their therapeutic effects both in vitro and in vivo
through a novel FBXW7 nuclear retention mediated NOTCH1 sup-
pression. CRM1 also known as Exportin 1 (Xpo1) is a protein that has
been found to be upregulated in PDAC cells, and blocks the activity of
tumor suppressor protein (TSP) through constant nuclear export.
Targeting CRM1 through specific inhibitors of nuclear export (SINE)
has earlier shown promise in the inhibition of pancreatic cancer cell
proliferation and growth. Most importantly, the inhibitor SINE KPT-
185 inhibits PDAC growth, migration, invasion, and triggers apoptosis
and G2-M cell cycle arrest at very low concentrations. The activity of
KPT-185 is strongly correlated to the nuclear retention of FBXW7;
which degrades nuclear N1-ICD, thereby leading to reduced expres-
sion of tumor-promoting markers like Cyclin-D1, c-Myc, VEGF, and
Hes-1. The orally bioavailable form of SINE (KPT-251) has shown tre-
mendous antitumor activity in a Colo-357 PDAC xenografts model.91
Likewise, there is a panel of bioactive compounds that have shown to
target the deregulated F-box protein in a range of tumors and are
listed in Table 2 below.
TABLE 2 Summary of bioactive compounds mediated targeting of SCF type E3 ligase components in cancer
Compounds F-box protein Associated mechanisms Associated cancer References
KL001 Fbxl3 Competes for binding in the FAD pocket of
CRYs and prevents Fbxl3 binding
Cancer, cardiovascular and metabolic
diseases
92,93
SINE KPT-185 FBXW7 Inhibits nuclear export of FBXW7, enhances
nuclear retention of FBXW7 and
degrades NOTCH1
Pancreatic cancer 91
Genistein FBXW7 Inhibits miR-223 expression and elevates its
target FBXW7 expression
Leukemia and lymphoma 94
Oridonin FBXW7 Increases FBXW7 expression, activates
GSK3, and facilitates c-Myc turnover
Leukemia and lymphoma 95
Erioflorin κ-TrCP Inhibits the interaction between κ-TrCP and
tumor suppressor Pdcd4
Cancer, general 96
GS143 κ-TrCP Disrupts interaction between phospho-
IκBκκ and κ-TrCP and suppress IκBκ
ubiquitylation
Inflammation 97
SMIP004 Skp2 Downregulates Skp2 Prostate cancer 98
Compound A (CpdA) Skp2 Interferes Skp2-Skp1 interaction and
stabilizes p27
Multiple myeloma 99
Compound #25 Skp2 Binds to Skp2 and prevents Skp2-Skp1
interaction
Cancer, general 100
C1, C2, C16, C20 Skp2 Binds to a pocket formed by Skp2 and Cks1
to block substrate binding
Metastatic melanoma, prostate, breast,
ovarian, and lung cancer
101
Curcumin Skp2 Natural agents, inhibit Skp2 expression Breast and prostate cancer 102-104
BC-1258 Fbxl2 Inhibits binding between Fbxo3 and Fbxl2,
stabilizes Fbxl2 and promotes Aurora B
degradation
Inflammation 105
BC-1215 Fbxl2 Inhibits the Fbxo3 and Fbxl2 binding Inflammation 106
Quercetin Skp2 Natural agents, inhibit Skp2 expression Breast and prostate cancer 102-104
Lycopene Skp2 Natural agents, inhibit Skp2 expression Breast and prostate cancer 102-104
Silibinin Skp2 Natural agents, inhibit Skp2 expression Breast and prostate cancer 102-104
Vitamin D Skp2 Natural agents, inhibit Skp2 expression Breast and prostate cancer 102-104
Epigallocatechin
gallate (EGCG)
Skp2 Natural agents, inhibit Skp2 expression Breast and prostate cancer 102-104
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9 | CONCLUDING REMARKS
FBXW7 and NOTCH based interactions cater to a panel of cellular
processes in the mammalian system, which under ideal conditions are
essential for maintaining normal cellular homeostasis. However,
FBXW7 and NOTCH activity can be deregulated due to incriminating
factors like a mutation that disturbs the homeostatic state, thereby
driving oncogenic transformation. In this current review, we discussed
about the recent advancements made in studying the disease-critical
interactions involving FBXW7 and NOTCH, which aberrantly drive
key biological processes, such as cell cycle, cellular proliferation,
metastasis, apoptosis, etc. Although at the very early stage of
research, we explored the possibility of utilizing FBXW7 as a novel
diagnostic marker in tumors. The FBXW7-NOTCH interactome is
extremely complex but from a therapeutic perspective it holds tre-
mendous promise. In that aspect, several biomolecules are now being
investigated for their unique ability to selectively target proteins
involved in the interactome. Moving forward, we sincerely believe
that unraveling the intricacies of this complex interactome may pro-
vide a therapeutic outlook for patients suffering from both solid and
nonsolid tumors and displaying extremely poor prognosis.
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